feladilimab + dostarlimab + cobolimab

This is a **combination immunotherapy regimen** composed of three monoclonal antibodies: **feladilimab** (GSK3359609, an anti-ICOS antibody), **dostarlimab** (Jemperli, an anti-PD-1 antibody), and **cobolimab** (an anti-TIM-3 antibody). - **Feladilimab** targets the Inducible T-cell COStimulator (ICOS) receptor, enhancing T-cell activation and antitumor activity. - **Dostarlimab** inhibits programmed cell death protein 1 (PD-1), releasing the inhibition of immune response against tumor cells. - **Cobolimab** inhibits T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), another immune checkpoint limiting antitumor immunity. This combination is under investigation for **solid tumors**, particularly metastatic or recurrent cancers, aiming to potentiate immune activation and antitumor efficacy by targeting multiple, non-redundant immune regulatory pathways[10]. Clinical trials focus on dose optimization, safety assessment, and preliminary efficacy in advanced cancers.